ライフサイエンスコーパス: norepinephrine transporter

1 e ((11)C-MRB, a ligand for the cell membrane norepinephrine transporter).

2 echolamines (uptake 1) via the cell membrane norepinephrine transporter.

3 on binding to monoamine oxidase A or to the norepinephrine transporter.

4 aining a small (34 amino acid) region of the norepinephrine transporter.

5 y, of which the most widely exploited is the norepinephrine transporter.

6 BG is known to enter tumor cells through the norepinephrine transporter.

7 small-molecule inhibitor of Rho kinase and a norepinephrine transporter.

8 , vesicular monoamine transporter 2, and the norepinephrine transporter.

9 ized single amino acid variants of the human norepinephrine transporter.

10 cy most closely resembling that of mammalian norepinephrine transporters.

11 highest affinity for both the serotonin and norepinephrine transporters.

12 nsporter (DAT) relative to the serotonin and norepinephrine transporters.

13 and almost 1000 times more potent at 5-HT vs norepinephrine transporters.

14 ve for the DAT compared to the serotonin and norepinephrine transporters.

15 , increased neu mRNA levels and lack of both norepinephrine transporter activity and nerve growth fac

16 en validated as a highly specific marker for norepinephrine transporter activity of the sympathetic n

17 DHD), which blocks dopamine transporters and norepinephrine transporters, ameliorated the behavioral

18 enzylguanidine (MIBG) scan for uptake by the norepinephrine transporter and [(18)F]fluorodeoxyglucose

19 0- and 28,000-fold selectivity for SERT over norepinephrine transporter and dopamine transporter, res

20 es of 1.19 and 16.5 nM for the serotonin and norepinephrine transporter and is thus a nonselective mo

21 h those of other SLC6 members, including the norepinephrine transporter and other GATs, to identify l

22 mpathetic nerve varicosities by the neuronal norepinephrine transporter and stored in vesicles.

23 mpathetic nerve varicosities by the neuronal norepinephrine transporter and taken up into storage ves

24 rotonin transporter, [3H]nisoxetine from the norepinephrine transporter, and [3H]pirenzepine from mus

25 ing affinities at the serotonin transporter, norepinephrine transporter, and muscarinic receptors wer

26 bind to the dopamine transporter (DAT), the norepinephrine transporter, and the serotonin transporte

27 transporters such as serotonin, dopamine, or norepinephrine transporters, and because of the resoluti

28 malian catecholamine transporters, including norepinephrine transporter- and DAT-selective antagonist

29 These findings indicate that norepinephrine transporters are capable of transporting

30 Using this method we demonstrate that norepinephrine transporters are efficient buffers for su

31 fering binding profiles at the serotonin and norepinephrine transporters as well as at muscarinic rec

32 Phenylalanine conversion in the human norepinephrine transporter at the homologous position fa

33 affinities for the dopamine, serotonin, and norepinephrine transporter binding sites were determined

34 termined by alpha2-adrenoreceptors (ARs) and norepinephrine transporter binding sites; and (3) sprout

35 techolamine levels and neural gain using the norepinephrine transporter blocker atomoxetine and demon

36 ctions of yohimbine were not mimicked by the norepinephrine transporter blocker reboxetine, they were

37 at SERT stimulation is shared with the human norepinephrine transporter but not the human dopamine tr

38 ical differences may reflect blockade of the norepinephrine transporter by cocaine but not by GBR-129

39 iscovery that a coding mutation in the human norepinephrine transporter contributes to orthostatic in

40 hypothesis that impaired functioning of the norepinephrine transporter contributes to the pathophysi

41 The norepinephrine transporter critically regulates both neu

42 )-cis analogues exhibit dopamine transporter/norepinephrine transporter (DAT/NET) selectivity as was

43 selective for the SERT over the dopamine and norepinephrine transporters (DAT and NET).

44 the behavior of the dopamine, serotonin, and norepinephrine transporters (DAT, SERT, NET) in the pres

45 ade of the dopamine transporter, but not the norepinephrine transporter, during P22-41 also increases

46 revealed increased glucose transporter-1 and norepinephrine transporter expression in BAT cell membra

47 We report reduced norepinephrine transporter expression, decreased intrace

48 ytime arousal, sleeping longer at night, and norepinephrine transporter expression.

49 of a single METH injection on serotonin and norepinephrine transporter function and effects of direc

50 e permits quantitative assessment of cardiac norepinephrine transporter function in active chronic co

51 s and associated with genetic variation in a norepinephrine transporter gene (n = 819).

52 f the present study was to determine whether norepinephrine transporter gene (NET) and serotonin tran

53 e transcription initiation site of the human norepinephrine transporter gene [solute carrier family 6

54 Eleven new mutations were found in the human norepinephrine transporter gene, although none were dire

55 pillover and clearance, and we sequenced the norepinephrine-transporter gene and evaluated its functi

56 Analysis of the norepinephrine-transporter gene revealed that the proban

57 lates expression of tyrosine hydroxylase and norepinephrine transporter genes in brain neurons; howev

58 transporters (i.e., serotonin, dopamine, and norepinephrine transporters) have been implicated as pla

59 The human dopamine and norepinephrine transporters (hDAT and hNET, respectively

60 s this limitation, we have evaluated a human norepinephrine transporter (hNET) permitting imaging of

61 cocaine- and antidepressant-sensitive human norepinephrine transporter (hNET) was assessed in stably

62 ries of compounds potently blocked the human norepinephrine transporter (hNET) while exhibiting selec

63 th retroviral vectors encoding for the human norepinephrine transporter (hNET), human sodium-iodide s

64 of porcine kidney cells expressing the human norepinephrine transporter (hNET).

65 amined whether paroxetine inhibits the human norepinephrine transporter in addition to the human sero

66 onic stimulation of tyrosine hydroxylase and norepinephrine transporter in brain neurons by angiotens

67 n binding to dopamine, serotonin (5-HT), and norepinephrine transporters in membranes from rat striat

68 nergic proteins (e.g., tyrosine hydroxylase, norepinephrine transporters) in the locus coeruleus has

69 (LNAA-) IP to lower brain tyrosine, and the norepinephrine transporter inhibitor desipramine (DMI) 1

70 In pharmacological blocking studies with the norepinephrine transporter inhibitor desipramine (DMI),

71 Applying norepinephrine or a norepinephrine transporter inhibitor reduced the amplitu

72 thalmic solution, a rho-kinase inhibitor and norepinephrine transporter inhibitor, in patients with o

73 trial of atomoxetine, a clinically-approved norepinephrine transporter inhibitor, in subjects with m

74 tiomers as a dual inhibitor of serotonin and norepinephrine transporters is in the low nanomolar rang

75 also has good affinity for the serotonin and norepinephrine transporters (K(i) = 21 and 6.5 nM, respe

76 In contrast, norepinephrine transporter knockout (NET-KO) mice have a

77 tion of a DAT-like substrate selectivity and norepinephrine transporter-like inhibitor pharmacology w

78 unoreactivity and radioligand binding to the norepinephrine transporter, monoamine oxidase A, and alp

79 A novel (18)F-labeled ligand for the norepinephrine transporter (N-[3-bromo-4-(3-(18)F-fluoro

80 AT) (K(i) = 268 nM) and good activity at the norepinephrine transporter (NET) (K(i) = 26 nM).

81 amine transporter (DAT) (Ki = 13 nM) and the norepinephrine transporter (NET) (Ki = 28 nM).

82 transported into sympathetic neurons by the norepinephrine transporter (NET) and stored in vesicles.

83 ttenuation of the Ang II-induced increase in norepinephrine transporter (NET) and tyrosine hydroxylas

84 Angiotensin II (Ang II) stimulates norepinephrine transporter (NET) and tyrosine hydroxylas

85 The expression of norepinephrine transporter (NET) and vesicular monoamine

86 -gated calcium channels (Ca(v)a2d-1) and the norepinephrine transporter (NET) are reported.

87 The serotonin transporter (SERT) and the norepinephrine transporter (NET) are sodium-dependent ne

88 nic stress is associated with a reduction in norepinephrine transporter (NET) availability in the loc

89 Norepinephrine transporter (NET) binding site concentrat

90 Norepinephrine transporter (NET) binding was significant

91 In vivo norepinephrine transporter (NET) blockade with desiprami

92 ongly increases PKC-dependent endocytosis of norepinephrine transporter (NET) but not of serotonin tr

93 pothesis that in the absence of the DAT, the norepinephrine transporter (NET) could provide an altern

94 ine self-administration on the regulation of norepinephrine transporter (NET) distribution and functi

95 -hydroxydopamine (6-OHDA)-lesioned striatum, norepinephrine transporter (NET) expression increases an

96 orrelated with histological tumor volume and norepinephrine transporter (NET) expression.

97 raft-mediated internalization of the native norepinephrine transporter (NET) following protein kinas

98 Therapeutic targeting of the norepinephrine transporter (NET) function with benzylgua

99 The norepinephrine transporter (NET) has recently been sugge

100 at the SERT, dopamine transporter (DAT) and norepinephrine transporter (NET) in native rodent tissue

101 ter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET) in the brain by measuri

102 ter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET) in the brain by measuri

103 ter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET) in the brain by measuri

104 t the DAT, serotonin transporter (SERT), and norepinephrine transporter (NET) in the brain by measuri

105 Selective blockers of the norepinephrine transporter (NET) inhibit dopamine uptake

106 Similar treatment with the norepinephrine transporter (NET) inhibitor, desipramine,

107 The norepinephrine transporter (NET) is a membrane protein r

108 The norepinephrine transporter (NET) is a presynaptic plasma

109 The norepinephrine transporter (NET) is a site of action for

110 Furthermore, the norepinephrine transporter (NET) is an important target

111 on and sympathetic nerve conduction, and the norepinephrine transporter (NET) is crucial in limiting

112 The norepinephrine transporter (NET) is essential for norepi

113 The human norepinephrine transporter (NET) is implicated in many n

114 ity and selectivity over the closely related norepinephrine transporter (NET) is not well understood.

115 The norepinephrine transporter (NET) is responsible for the

116 The norepinephrine transporter (NET) mediates reuptake of no

117 The norepinephrine transporter (NET) mediates reuptake of sy

118 e indoline ring enhanced selectivity for the norepinephrine transporter (NET) over the serotonin tran

119 The norepinephrine transporter (NET) regulates noradrenergic

120 The norepinephrine transporter (NET) substrates [123I]-m-iod

121 we demonstrated a role for p38 MAPK-mediated norepinephrine transporter (NET) Thr(30) phosphorylation

122 The norepinephrine transporter (NET) transports norepinephri

123 human SERT, dopamine transporter (DAT), and norepinephrine transporter (NET) using [(3)H]citalopram,

124 human SERT, dopamine transporter (DAT), and norepinephrine transporter (NET) using [(3)H]citalopram,

125 antly in the apical plasma membrane, whereas norepinephrine transporter (NET) was found in the basola

126 trated that 1-4 have a high affinity for the norepinephrine transporter (NET) with K(i)'s = 1.02, 3.1

127 tudies in cells transfected with human SERT, norepinephrine transporter (NET), and dopamine transport

128 inities to the monoamine transporters (SERT, norepinephrine transporter (NET), and dopamine transport

129 bitors of the dopamine transporter (DAT) and norepinephrine transporter (NET), and low Na(+) produced

130 sporter (DAT), serotonin transporter (SERT), norepinephrine transporter (NET), and muscarinic (M(1))

131 nobutyric acid type A (GABAa) receptors, the norepinephrine transporter (NET), and their encoding mRN

132 rs of the dopamine transporter (DAT) and the norepinephrine transporter (NET), but they were less pot

133 In norepinephrine transporter (NET), cysteine replacement o

134 iated osteoblasts, like neurons, express the norepinephrine transporter (NET), exhibit specific NE up

135 dopamine beta-hydroxylase (DbetaH), and the norepinephrine transporter (NET), in part, by influencin

136 ds to the dopamine transporter (DAT) and the norepinephrine transporter (NET), to unravel its effects

137 The norepinephrine transporter (NET), which is expressed on

138 Expression of the norepinephrine transporter (NET), which mediates the reu

139 2), which packages NE into vesicles, and the norepinephrine transporter (NET), which removes NE from

140 addition, pharmacological inhibition of the norepinephrine transporter (NET), which serves to remove

141 bition at the dopamine transporter (DAT) and norepinephrine transporter (NET), with weaker effects at

142 Similarly, lack of NE reuptake in norepinephrine transporter (Net)-deficient mice led to r

143 , 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density.

144 ), the serotonin transporter (SERT), and the norepinephrine transporter (NET).

145 ls but inhibited the function of the related norepinephrine transporter (NET).

146 time with a corresponding sequence from the norepinephrine transporter (NET).

147 noradrenergic nerve endings, mediated by the norepinephrine transporter (NET).

148 tic nerve radiotracers are substrates of the norepinephrine transporter (NET).

149 s for both the DAT and 5-HTT relative to the norepinephrine transporter (NET).

150 ), the serotonin transporter (SERT), and the norepinephrine transporter (NET).

151 at DAT (EC50 approximately 35 nM) and at the norepinephrine transporter (NET).

152 ), the serotonin transporter (SERT), and the norepinephrine transporter (NET).

153 l esters (8a-h) showed high affinity for the norepinephrine transporter (NET).

154 y with (131)I-mIBG, a substrate of the human norepinephrine transporter (NET-1), shows promising resp

155 over serotonin transporter (SERT/DAT = 94), norepinephrine transporter (NET/DAT = 63), and sigma(1)

156 osing changes of the mRNA expression for the norepinephrine transporter (NET; decreased) and the dopa

157 essing SERT, dopamine transporters (DAT), or norepinephrine transporters (NET) showed excellent bindi

158 ver serotonin transporters (SERT; 989-fold), norepinephrine transporters (NET; 261-fold) and muscarin

159 CAs), such as desipramine (DMI), which block norepinephrine transporters (NETs), also produce mild an

160 amine via cocaine- and amphetamine-sensitive norepinephrine transporters (NETs).

161 for indices of function of the cell membrane norepinephrine transporter, norepinephrine synthesis, an

162 differences were found in GAD+ somata, or in norepinephrine transporter or serotonin transporter immu

163 h are potent and selective inhibitors of the norepinephrine transporter over both the serotonin and d

164 The gene encoding the norepinephrine transporter protein (SLC6A2) maps to this

165 tine binding to the dopamine, serotonin, and norepinephrine transporters, respectively.

166 l mice, but responded similarly to SERT- and norepinephrine transporter-selective antidepressants.

167 (DAT) affinity relative to the serotonin and norepinephrine transporters (SERT and NET, respectively)

168 inding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and NET, respect

169 ne oxidases A and B and at the serotonin and norepinephrine transporters) showed antidepressant-like

170 e five putatively functional variants of the norepinephrine transporter (SLC6A2, NET) and serotonin t

171 carriers and is functional in the homologous norepinephrine transporter, suggesting that this region

172 ing affinity at the dopamine, serotonin, and norepinephrine transporter systems in rat brain.

173 ing affinity at the dopamine, serotonin, and norepinephrine transporter systems in the brain by compe

174 selectivity toward DAT versus serotonin and norepinephrine transporters than modafinil.

175 d that is a potent inhibitor of dopamine and norepinephrine transporters that achieves stable plasma

176 dinium) has micromolar potency for the human norepinephrine transporter, that ASP(+) accumulation is

177 ding studies at the dopamine, serotonin, and norepinephrine transporters using [(125)I]RTI-55 in clon

178 mouse dopamine transporter (V152M) or human norepinephrine transporter (V148M) result in transporter

179 upling protein-1, glucose transporter-1, and norepinephrine transporter was evaluated with immunohist

180 mpound to the human serotonin, dopamine, and norepinephrine transporters was determined using transfe

181 Binding selectivity for dopamine versus norepinephrine transporters was greater for (+)-2 than f

182 ntrast, none of the analogues recognized the norepinephrine transporter with an affinity of <1.3 micr

183 abuse, bind to dopamine (DA), serotonin, and norepinephrine transporters with high affinity and block

184 ded selective inhibitors of the dopamine and norepinephrine transporters with little effect upon sero